These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
654 related articles for article (PubMed ID: 19642194)
1. Neurodevelopmental consequences of Smn depletion in a mouse model of spinal muscular atrophy. Liu H; Shafey D; Moores JN; Kothary R J Neurosci Res; 2010 Jan; 88(1):111-22. PubMed ID: 19642194 [TBL] [Abstract][Full Text] [Related]
2. Smn deficiency causes neuritogenesis and neurogenesis defects in the retinal neurons of a mouse model of spinal muscular atrophy. Liu H; Beauvais A; Baker AN; Tsilfidis C; Kothary R Dev Neurobiol; 2011 Feb; 71(2):153-69. PubMed ID: 20862739 [TBL] [Abstract][Full Text] [Related]
3. SAHA ameliorates the SMA phenotype in two mouse models for spinal muscular atrophy. Riessland M; Ackermann B; Förster A; Jakubik M; Hauke J; Garbes L; Fritzsche I; Mende Y; Blumcke I; Hahnen E; Wirth B Hum Mol Genet; 2010 Apr; 19(8):1492-506. PubMed ID: 20097677 [TBL] [Abstract][Full Text] [Related]
4. Neurodevelopmental abnormalities in neurosphere-derived neural stem cells from SMN-depleted mice. Shafey D; MacKenzie AE; Kothary R J Neurosci Res; 2008 Oct; 86(13):2839-47. PubMed ID: 18521935 [TBL] [Abstract][Full Text] [Related]
5. Valproic acid increases the SMN2 protein level: a well-known drug as a potential therapy for spinal muscular atrophy. Brichta L; Hofmann Y; Hahnen E; Siebzehnrubl FA; Raschke H; Blumcke I; Eyupoglu IY; Wirth B Hum Mol Genet; 2003 Oct; 12(19):2481-9. PubMed ID: 12915451 [TBL] [Abstract][Full Text] [Related]
6. Is RNA manipulation a viable therapy for spinal muscular atrophy? Horne C; Young PJ J Neurol Sci; 2009 Dec; 287(1-2):27-31. PubMed ID: 19758605 [TBL] [Abstract][Full Text] [Related]
7. SMN deficiency alters Nrxn2 expression and splicing in zebrafish and mouse models of spinal muscular atrophy. See K; Yadav P; Giegerich M; Cheong PS; Graf M; Vyas H; Lee SG; Mathavan S; Fischer U; Sendtner M; Winkler C Hum Mol Genet; 2014 Apr; 23(7):1754-70. PubMed ID: 24218366 [TBL] [Abstract][Full Text] [Related]
8. p38 Mitogen-activated protein kinase stabilizes SMN mRNA through RNA binding protein HuR. Farooq F; Balabanian S; Liu X; Holcik M; MacKenzie A Hum Mol Genet; 2009 Nov; 18(21):4035-45. PubMed ID: 19648294 [TBL] [Abstract][Full Text] [Related]
9. LBH589 induces up to 10-fold SMN protein levels by several independent mechanisms and is effective even in cells from SMA patients non-responsive to valproate. Garbes L; Riessland M; Hölker I; Heller R; Hauke J; Tränkle C; Coras R; Blümcke I; Hahnen E; Wirth B Hum Mol Genet; 2009 Oct; 18(19):3645-58. PubMed ID: 19584083 [TBL] [Abstract][Full Text] [Related]
10. A sensitive assay for measuring SMN mRNA levels in peripheral blood and in muscle samples of patients affected with spinal muscular atrophy. Vezain M; Saugier-Veber P; Melki J; Toutain A; Bieth E; Husson M; Pedespan JM; Viollet L; Pénisson-Besnier I; Fehrenbach S; Bou J; Frébourg T; Tosi M Eur J Hum Genet; 2007 Oct; 15(10):1054-62. PubMed ID: 17609673 [TBL] [Abstract][Full Text] [Related]
11. Synthesis and biological evaluation of novel 2,4-diaminoquinazoline derivatives as SMN2 promoter activators for the potential treatment of spinal muscular atrophy. Thurmond J; Butchbach ME; Palomo M; Pease B; Rao M; Bedell L; Keyvan M; Pai G; Mishra R; Haraldsson M; Andresson T; Bragason G; Thosteinsdottir M; Bjornsson JM; Coovert DD; Burghes AH; Gurney ME; Singh J J Med Chem; 2008 Feb; 51(3):449-69. PubMed ID: 18205293 [TBL] [Abstract][Full Text] [Related]
12. Diverse small-molecule modulators of SMN expression found by high-throughput compound screening: early leads towards a therapeutic for spinal muscular atrophy. Jarecki J; Chen X; Bernardino A; Coovert DD; Whitney M; Burghes A; Stack J; Pollok BA Hum Mol Genet; 2005 Jul; 14(14):2003-18. PubMed ID: 15944201 [TBL] [Abstract][Full Text] [Related]
13. Survival motor neuron SMN1 and SMN2 gene promoters: identical sequences and differential expression in neurons and non-neuronal cells. Boda B; Mas C; Giudicelli C; Nepote V; Guimiot F; Levacher B; Zvara A; Santha M; LeGall I; Simonneau M Eur J Hum Genet; 2004 Sep; 12(9):729-37. PubMed ID: 15162126 [TBL] [Abstract][Full Text] [Related]
15. Development and characterization of an SMN2-based intermediate mouse model of Spinal Muscular Atrophy. Cobb MS; Rose FF; Rindt H; Glascock JJ; Shababi M; Miller MR; Osman EY; Yen PF; Garcia ML; Martin BR; Wetz MJ; Mazzasette C; Feng Z; Ko CP; Lorson CL Hum Mol Genet; 2013 May; 22(9):1843-55. PubMed ID: 23390132 [TBL] [Abstract][Full Text] [Related]
16. Therapeutics that directly increase SMN expression to treat spinal muscular atrophy. Shababi M; Mattis VB; Lorson CL Drug News Perspect; 2010 Oct; 23(8):475-82. PubMed ID: 21031163 [TBL] [Abstract][Full Text] [Related]
17. Genetic conversion of an SMN2 gene to SMN1: a novel approach to the treatment of spinal muscular atrophy. DiMatteo D; Callahan S; Kmiec EB Exp Cell Res; 2008 Feb; 314(4):878-86. PubMed ID: 18078930 [TBL] [Abstract][Full Text] [Related]
18. The importance of the SMN genes in the genetics of sporadic ALS. Corcia P; Camu W; Praline J; Gordon PH; Vourch P; Andres C Amyotroph Lateral Scler; 2009; 10(5-6):436-40. PubMed ID: 19922137 [TBL] [Abstract][Full Text] [Related]
19. Expression profiling in spinal muscular atrophy reveals an RNA binding protein deficit. Anderson KN; Baban D; Oliver PL; Potter A; Davies KE Neuromuscul Disord; 2004 Nov; 14(11):711-22. PubMed ID: 15482955 [TBL] [Abstract][Full Text] [Related]
20. SMN genotypes producing less SMN protein increase susceptibility to and severity of sporadic ALS. Veldink JH; Kalmijn S; Van der Hout AH; Lemmink HH; Groeneveld GJ; Lummen C; Scheffer H; Wokke JH; Van den Berg LH Neurology; 2005 Sep; 65(6):820-5. PubMed ID: 16093455 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]